Advancing Humane Science – Fabrice Barlesi

In this episode, Fabrice Barlesi, CEO of Gustave Roussy, who is a lung cancer specialist, shares his personal journey into the field of medicine and oncology, highlighting a pivotal moment with a patient that shaped his dedication to this field. The conversation delves into leadership in the context of healthcare. Fabrice emphasizes the need for leaders to take responsibility and give credit, stressing the critical role of attracting talented individuals to an organization. The discussion also touches on precision medicine and its transformative impact on cancer care. Fabrice shares his insights on the future of oncology, focusing on early detection, precision medicine, and immunotherapy as key drivers in improving patient outcomes. Throughout the conversation, Fabrice's passion for advancing oncology and improving patient care shines through, making it clear why he has been recognized as one of the world's most influential researchers in his field. We're sure you'll enjoy the full conversation!

"Oncology is the perfect mix of Science and Human"

MEET OUR GUEST Fabrice Barlesi CEO of Gustave Roussy, a leading cancer center in Europe, ranked third world's best oncology hospital and first outside the United States.

Fabrice Barlesi is Chief Executive Officer of Gustave Roussy. Fabrice is a lung cancer specialist and a major contributor to research in the field of novel oncological therapies. He was appointed Chief Medical Officer and then CEO of Gustave Roussy in 2020.

Fabrice is a Professor of Medicine at the University of Aix-Marseille and joined Paris Saclay University in 2022. He has been head of the Multidisciplinary Oncology and Innovative Therapies Department of the Nord Hospital in Marseille and the Marseille Centre for Early Trials in Oncology (CLIP2) which were established by him. Fabrice is also co-founder of the Marseille Immunopôle French Immunology network.

Fabrice is the author and co-author of some 400 articles in international journals and specialist publications. In 2018, the European Society of Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) awarded him the prestigious Heine H. Hansen Prize. He appears in the 2019 World List of most influential researchers.